Lisinopril/amlodipine
Combination of | |
---|---|
Lisinopril | ACE inhibitor |
Amlodipine | Calcium channel blocker |
Names | |
Trade names | Lisonorm, Dironorm, others |
Clinical data | |
Routes of use | By mouth |
Defined daily dose | not established[1] |
Legal | |
Legal status |
|
Lisinopril/amlodipine, sold under the brand name Lisonorm among others, is a medication used to treat high blood pressure.[2] It is a combination of lisinopril an ACE inhibitor with amlodipine a calcium channel blocker.[2] It may be used when blood pressure is well controlled with each of the two agents alone.[3] It is taken by mouth.[2]
Side effects may include low blood pressure, kidney problems, liver problems, cough, and high blood potassium.[3] It should not be used in people who have previously had angioedema due to ACE inhibitors.[3] Use is not recommended during pregnancy or breastfeeding.[3] Lisinopril works by decreasing angiotensin II and increasing bradykinin while amlodipine decreases the entry of calcium into the muscle cells in the heart and blood cells.[3]
The combination was approved for medical use in Europe in 2008.[2] The combination is on the World Health Organization's List of Essential Medicines.[4] While it is available in India and Europe it is not available in Canada, Australia, or the United States as of 2019.[5]
Dosage
The defined daily dose is not established.[1]
References
- 1 2 "WHOCC - ATC/DDD Index". www.whocc.no. Archived from the original on 1 July 2021. Retrieved 10 September 2020.
- 1 2 3 4 "Lisonorm". European Medicines Agency. 17 September 2018. Archived from the original on 24 March 2020. Retrieved 30 October 2019.
- 1 2 3 4 5 "Summary of Product Characteritics" (PDF). EMA. Archived (PDF) from the original on 30 October 2019. Retrieved 15 November 2019.
- โ "World Health Organization model list of essential medicines: 21st list 2019". 2019. hdl:10665/325771.
{{cite journal}}
: Cite journal requires|journal=
(help) - โ "An application to include blood pressure lowering drug fixed dose combinations to the model list of essential medicines lists for the treatment of essential hypertension in adults" (PDF). WHO. p. 33. Archived (PDF) from the original on 24 March 2020. Retrieved 15 November 2019.
External links
Identifiers: |
---|